The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.
Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.
These factors are likely to drive the respiratory antiviral treatment market.
Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.
Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.
Several new direct-acting influenza antivirals have been introduced in the respiratory antiviral treatment market. As such, baloxavir marboxil has been approved in the U.S., which is an antiviral for the treatment of influenza. However, there is a need to develop a universal influenza vaccine. Hence, healthcare companies are increasing their R&D capabilities to propose strategic plans ahead of government agencies with the help of field experts. On the other hand, manufacturers in the respiratory antiviral treatment market are increasing efforts to improve current seasonal influenza vaccines.
In order to tap into incremental opportunities in Europe, manufacturers are developing intravenous zanamivir-like antivirals, which is the only licensed treatment for influenza. This explains why the market is projected to expand at a CAGR of ~6% during the assessment period. Companies are achieving clinical developments in selected neuraminidase inhibitors, host-directed therapies, and selected polymerase inhibitors. Celdara Medical— a biotechnology-based company in the U.S. is gaining recognition for receiving Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop antivirals for COVID-19 and influenza.
The respiratory antiviral treatment market is expected to surpass revenue of US$ 5.3 Bn by the end of 2030. However, the issue of antiviral resistance is emerging as a restraint for market growth. For instance, M2 ion-channel inhibitors and neuraminidase (NA) inhibitors are approved treatments for influenza; however, they are associated with drug resistance in individuals. As such, neuraminidase inhibitors are being used on an extensive scale as an anti-influenza drug, since this treatment is less susceptible to drug resistance.
Since drug resistance has led to increased cost of patient healthcare, companies in the respiratory antiviral treatment market are shifting their business models toward the development of vaccines to curb the spread of respiratory illnesses. Since coinfection of pneumonia and influenza has led to increased morbidity and mortality, healthcare providers are adopting optimal control strategies.
The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.
Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.
Companies in the respiratory antiviral treatment market are innovating in antiviral drugs to treat measles. However, their effectiveness after central nervous system (CNS) manifestations remain to be evaluated. Companies in the respiratory antiviral treatment market are experimenting with immunoglobulins to treat measles infection. The combination treatment is being highly publicized for measles treatment, which involves the use of immunoglobulins with antiviral drugs to reduce signs and symptoms.
Ribavirin is a popular antiviral drug used for the treatment of measles infection. The combination of ribavirin and immune serum globulin holds promising potentials to reduce respiratory symptoms of measles. Companies are conducting clinical trials to identify whether the action of vitamin A helps in the treatment of measles. Though vaccines are considered as the most efficient prevention of against measles, the decreasing coverage combined to the increasing number of immunocompromised people difficult to vaccinate confirm the necessity to develop efficient antiviral drugs.
Analysts’ Viewpoint
Healthcare institutes are offering funding to biotech companies to develop antiviral drugs that treat influenza and COVID-19. Direct-acting influenza antivirals are being preferred by healthcare providers to minimize symptoms of respiratory illnesses in patients. However, drug resistance is emerging as a problem in healthcare settings, resulting in increased cost of hospital stay. Hence, companies in the respiratory antiviral treatment market should increase awareness about optimal control strategies such as vaccines and isolation, if patients have low immune response toward antiviral drugs. The combination treatment of immunoglobulins with antiviral drugs helps to reduce signs and symptoms of the measles infection. Ribavirin is being highly publicized as an antiviral drug for the treatment of measles.
Respiratory antiviral treatment market to cross valuation of US$ 5.3 Bn by 2030
Respiratory antiviral treatment market is projected to expand at a CAGR of ~6% from 2020 to 2030
Respiratory antiviral treatment market is driven by rise in prevalence and incidence of respiratory viral diseases
North America accounted for a major share of the global respiratory antiviral treatment market
Key players operating in the global market include F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Respiratory Antiviral Treatment Market Forecast
4.5. Global Respiratory Antiviral Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence Rate Globally with Key Countries
5.3. COVID-19 Impact Analysis
6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
6.1. Introduction
6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class
6.3.1. Nucleoside Analogs
6.3.1.1. Ribavirin
6.3.1.2. Aciclovir
6.3.1.3. Others
6.3.2. Neuraminidase Inhibitors
6.3.2.1. Oseltamivir
6.3.2.2. Zanamivir
6.3.2.3. Others
6.3.3. Ion Channel Blockers
6.3.4. Fusion Protein Inhibitors
6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
7.1. Introduction
7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type
7.3.1. Influenza
7.3.2. Bronchiolitis
7.3.3. Pneumonia
7.3.4. Upper Respiratory Tract Infections (URTIs)
7.3.5. Others (measles, etc.)
7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration
9. Global Respiratory Antiviral Treatment Market Analysis, by Region
9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country
9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Respiratory Antiviral Treatment Market Analysis
10.1. North America Respiratory Antiviral Treatment Market Overview
10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country
10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class
10.5.1. Nucleoside Analogs
10.5.1.1. Ribavirin
10.5.1.2. Aciclovir
10.5.1.3. Others
10.5.2. Neuraminidase Inhibitors
10.5.2.1. Oseltamivir
10.5.2.2. Zanamivir
10.5.2.3. Others
10.5.3. Ion Channel Blockers
10.5.4. Fusion Protein Inhibitors
10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type
10.7.1. Influenza
10.7.2. Bronchiolitis
10.7.3. Pneumonia
10.7.4. Upper Respiratory Tract Infections (URTIs)
10.7.5. Others (measles, etc.)
10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
10.9.1. Hospital Pharmacies
10.9.2. Retail Pharmacies
10.9.3. Online Pharmacies
11. Europe Respiratory Antiviral Treatment Market Analysis
11.1. Europe Respiratory Antiviral Treatment Market Overview
11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class
11.5.1. Nucleoside Analogs
11.5.1.1. Ribavirin
11.5.1.2. Aciclovir
11.5.1.3. Others
11.5.2. Neuraminidase Inhibitors
11.5.2.1. Oseltamivir
11.5.2.2. Zanamivir
11.5.2.3. Others
11.5.3. Ion Channel Blockers
11.5.4. Fusion Protein Inhibitors
11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type
11.7.1. Influenza
11.7.2. Bronchiolitis
11.7.3. Pneumonia
11.7.4. Upper Respiratory Tract Infections (URTIs)
11.7.5. Others (measles, etc.)
11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
11.9.1. Hospital Pharmacies
11.9.2. Retail Pharmacies
11.9.3. Online Pharmacies
12. Asia Pacific Respiratory Antiviral Treatment Market Analysis
12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview
12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class
12.5.1. Nucleoside Analogs
12.5.1.1. Ribavirin
12.5.1.2. Aciclovir
12.5.1.3. Others
12.5.2. Neuraminidase Inhibitors
12.5.2.1. Oseltamivir
12.5.2.2. Zanamivir
12.5.2.3. Others
12.5.3. Ion Channel Blockers
12.5.4. Fusion Protein Inhibitors
12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type
12.7.1. Influenza
12.7.2. Bronchiolitis
12.7.3. Pneumonia
12.7.4. Upper Respiratory Tract Infections (URTIs)
12.7.5. Others (measles, etc.)
12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
12.9.1. Hospital Pharmacies
12.9.2. Retail Pharmacies
12.9.3. Online Pharmacies
13. Latin America Respiratory Antiviral Treatment Market Analysis
13.1. Latin America Respiratory Antiviral Treatment Market Overview
13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class
13.5.1. Nucleoside Analogs
13.5.1.1. Ribavirin
13.5.1.2. Aciclovir
13.5.1.3. Others
13.5.2. Neuraminidase Inhibitors
13.5.2.1. Oseltamivir
13.5.2.2. Zanamivir
13.5.2.3. Others
13.5.3. Ion Channel Blockers
13.5.4. Fusion Protein Inhibitors
13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type
13.7.1. Influenza
13.7.2. Bronchiolitis
13.7.3. Pneumonia
13.7.4. Upper Respiratory Tract Infections (URTIs)
13.7.5. Others (measles, etc.)
13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
13.9.1. Hospital Pharmacies
13.9.2. Retail Pharmacies
13.9.3. Online Pharmacies
14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis
14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview
14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class
14.5.1. Nucleoside Analogs
14.5.1.1. Ribavirin
14.5.1.2. Aciclovir
14.5.1.3. Others
14.5.2. Neuraminidase Inhibitors
14.5.2.1. Oseltamivir
14.5.2.2. Zanamivir
14.5.2.3. Others
14.5.3. Ion Channel Blockers
14.5.4. Fusion Protein Inhibitors
14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type
14.7.1. Influenza
14.7.2. Bronchiolitis
14.7.3. Pneumonia
14.7.4. Upper Respiratory Tract Infections (URTIs)
14.7.5. Others (measles, etc.)
14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
14.9.1. Hospital Pharmacies
14.9.2. Retail Pharmacies
14.9.3. Online Pharmacies
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Pfizer, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Teva Pharmaceutical Industries Ltd.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Sun Pharmaceutical Industries Ltd.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. GlaxoSmithKline plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Mylan, Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. Merck & Co., Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. AstraZeneca plc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
List of Tables
Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Respiratory Antiviral Treatment Market Value Share, by Drug Class, 2019
Figure 03: Global Respiratory Antiviral Treatment Market Value Share, by Distribution Channel, 2019
Figure 04: Global Respiratory Antiviral Treatment Market Value Share, by Disease Type, 2019
Figure 05: Global Respiratory Antiviral Treatment Market Value Share, by Region, 2019
Figure 06: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 07: Global Respiratory Antiviral Treatment Market Attractiveness, by Drug Class, 2020–2030
Figure 08: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Nucleoside Analogs, 2018–2030
Figure 09: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Neuraminidase Inhibitors, 2018–2030
Figure 10: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Ion Channel Blockers, 2018–2030
Figure 11: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Fusion Protein Inhibitors, 2018–2030
Figure 12: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 13: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 14: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Influenza, 2018–2030
Figure 15: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Bronchiolitis, 2018–2030
Figure 16: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Pneumonia, 2018–2030
Figure 17: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Upper Respiratory Tract Infections (URTIs), 2018–2030
Figure 18: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Others (Measles, etc.), 2018–2030
Figure 19: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 20: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 21: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 22: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 23: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2018–2030
Figure 24: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 25: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Region
Figure 26: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 27: North America Respiratory Antiviral Treatment Market Value Share (%), by Country, 2019 and 2030
Figure 28: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country, 2020–2030
Figure 29: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 30: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 31: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 32: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 33: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 34: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 35: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 36: Europe Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 37: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 38: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 39: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 40: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 41: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 42: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 43: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 44: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 45: Asia Pacific Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 46: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 47: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 48: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 49: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 50: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 51: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 52: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 53: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 54: Latin America Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 55: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 56: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 57: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 58: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 59: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 60: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 61: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 62: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 63: Middle East & Africa Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 64: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 65: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 66: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 67: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030
Figure 68: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030
Figure 69: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 70: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Antiviral Treatment Market
